Amgen Inc. (AMGN.MX)


Mexico - Mexico Delayed Price. Currency in MXN
3,192.580.00 (0.00%)
As of 3:30 PM EDT. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open3,188.78
Prev Close3,192.58
Bid0.00 x 1300
Ask0.00 x 100000
Day's Range3,188.78 - 3,198.60
52wk Range2,252.38 - 3,288.37
1y Target EstN/A
Market Cap2.39T
P/E Ratio (ttm)326.71
BetaN/A
Volume24,158
Avg Vol (3m)1,293
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • PR Newswireyesterday

    Amgen Announces Positive Top-Line Results From Phase 3 Study Of Prolia® (Denosumab) In Patients Receiving Glucocorticoid Therapy

    THOUSAND OAKS, Calif., Aug. 29, 2016 /PRNewswire/ -- Amgen (AMGN) today announced positive top-line results from the primary analysis conducted in a Phase 3 randomized, double-blind, double-dummy, active-controlled study evaluating the safety and efficacy of Prolia® (denosumab) compared with risedronate in patients receiving glucocorticoid treatment. "The impact of glucocorticoid therapy on bone strength is frequently underestimated, and often leads to increased bone loss and ultimately, a fracture," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

  • PR Newswireyesterday

    New Repatha® (evolocumab) Analyses Show Efficacy And Safety Across Risk Groups In Results Presented At ESC Congress 2016

    "These analyses continue to shape the clinical evidence for Repatha and help to advance our understanding of its potential to benefit patients," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. Researchers looking at the "Efficacy of evolocumab in patients across ESC/EAS CV risk subgroups," categorized a total of 2,532 patients from three, 12-week Phase 3 studies by the four ESC/European Atherosclerotic Society (EAS) risk criteria (very high, high, moderate and low). The analysis showed that treatment with Repatha 140 mg every two weeks or 420 mg monthly consistently reduced levels of LDL-C and other lipids from baseline to the mean of weeks 10 and 12 across all risk categories compared to placebo or ezetimibe controls.

  • These Next-Generation Cholesterol Drugs Could Raise U.S. Healthcare Costs by $119 Billion a Year
    Motley Fool3 days ago

    These Next-Generation Cholesterol Drugs Could Raise U.S. Healthcare Costs by $119 Billion a Year

    PCSK-9 inhibitors lowered LDL-C by roughly 60% in clinical trials, but do their costs far outweigh their benefits?